Rheumnow

Drs. Jack Cush and Martin Bergman gather to review the topic of treat-to-target (T2T) management in rheumatology.  Both will debate the pro's and con's of the T2T strategy at the upcoming RWCS meeting on Feb. 17, 2022. You can register and learn more about the meeting at: https://r-w-c-s.com/2022/

Dr. Jack Cush discusses the evolution and future of telemedicine in rheumatology with the telemedicine guru - Dr. Alvin Wells

Dr. Jack Cush interviews Professor Edward Keystone, MD (from the University of Toronto) on the origins and science behind the 60/40/20 benchmark and outcomes in rheumatoid arthritis.

Panelists: Drs. Antoni Chan, Robert Chao, Rachel Tate, Sheila Reyes and Akhil Sood.

An Interview with Dr. Kaleb Michaud on Abstract 1158 from #ACR21

ALPN-303 - Dr. Pedro Castillo Dr. Castillo reports on abstract #1429 presented at the ACR21 annual meeting.

JAK Safety -- The Lowdown on Infection: Drs. Kevin Winthrop and Jonathan Kay Infections in ORAL Surveillance: Drs. Kevin Winthrop and Jonathan Kay Infliximab Drug Monitoring in PsA, RA, AxSpA: Dr. Pedro Castillo Lupus and Pregnancy: Dr. Sheila Reyes Secukinumab Effect on CV Risks in PsA, axSpA: Dr. Sheila Reyes

Spondyloarthritis Roundtable Rehash of ACR 2021

Giant Cell Arteritis and Polymyalgia Rheumatic Wrapup: Drs. Calabrese, Liew, Conway and Mackie

Reproductive Health in Rheumatic Diseases: Drs. Bermas, Buyon and Dao

The Expert Gout Panel with Drs. Neogi, Saag, Pillinger, Cush and O'Dell

Tofacitinib and Malignancy Risk: Dr. Seoyoung Kim Potpourri of Biosimilar Trials: Dr. Jonathan Kay Closing a Chapter: Interview with the 84th ACR President 2020-2021, Kathryn Dao

RheumNow Rheumatology Roundup- Drs.  Kavanaugh and Cush

TNF Inhibitor Panel Discussion- ACR21 Annual Meeting

Psoriatric Arthritis Panel Discussion- ACR21

RA Panel- Safety, Multimorbidities, Vaccination and the Weather

Glucocorticoids and CV risk in RA: Drs. Aurelie Najm and Jon Giles Might Tofacitinib Reduce Malignancy Risk with Patients with RA? Dr. Jonathan Kay Rheumatic Diseases Can Take your Breath Away: Dr.Janet Pope Best of PsA Day 4 (Tuesday): MACE in PsA:  Dr. Rachel Tate Predicting Progression from Psoriasis to PsA: Dr. Robert Chao David Liew Interview Dr. Seoyoung Kim About Tofacitinib and Malignancy Risk. Third Time's the Charm - COVID Vaccination While on Rituximab: Dr. Yuz Yusof Can We Stop Medication in Systemic JIA? Dr. Bella Mehta Day 4 SpA Highlights - Pregnancy in SpA and Drug Monitoring: Dr. Robert Chao

Diagnosing (Bad) VEXAS: The Experts Speak with Drs. Cush, Beck and Ferrada CV Risks and Gout T2T - An Interview with Dr. Seoyoung Kim, Kathryn Dao

Dr. Michelle Petri - Urine Proteome Advances: What Do They Mean? "Doctor, I Can Tell When It's Raining!" - Dr. Aurelie Najm NSAIDS Prevent Heart Attacks in PsA: Dr. Richard Conway Pediatric Psoriatic Arthritis: Dr. Eric Ruderman irAEs: Drs. Cassie Calabrese and David Liew TNFi in axSpA: Dr. Swetha Alexander

Sex, Age and Race/Ethnic Differences in Multimorbidity in Lupus: Drs. Duarte and Mehta Hospitalization Trends in Patients with Psoriatic Arthritis: Dr. Olga Petryna Patient Reported Outcomes in axSpA: Dr. Swetha Alexander Pregnancy Outcomes in PsA, SpA, RA: Dr. Rachel Tate Guselkemab vs. Ustekinumab in PsA: Dr. Richard Conway Medication Preferences in Patients with Psoriatic Arthritis: Dr. Olga Petryna Dr. Michelle Petri - Urine Proteome Advances: What Do They Mean?